Pipeline Progress And New Launches Will Secure Durable Long Term Earnings Power

Catalysts

About Takeda Pharmaceutical

Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty medicines across areas such as gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines.

What are the underlying business or industry changes driving this perspective?

• The planned launches of oveporexton and rusfertide over the next 12 months, together with zasocitinib in psoriasis around 2027, position Takeda to add new high value products that management believes can more than offset expected ENTYVIO biosimilar pressure in the early 2030s. This is aimed squarely at supporting revenue and earnings durability.
• The late stage pipeline now includes eight programs, including two oncology assets from Innovent Biologics, each described by management as having potential to transform standards of care. If successfully approved and adopted, these could broaden Takeda’s revenue mix and support longer term core operating profit.
• Oveporexton is the first orexin agonist submitted to the FDA, with strong Phase III data across all primary and secondary endpoints in narcolepsy type 1. This gives Takeda a first mover position in a growing neuroscience segment that could support premium pricing and attractive margins.
• Zasocitinib’s Phase III psoriasis results, with rapid skin clearance and once daily oral dosing, are at the high end of what management has seen for oral therapies. Potential expansion into psoriatic arthritis and inflammatory bowel disease could create a multi indication asset that supports both revenue growth and earnings scale.
• Management is combining tight cost discipline with targeted investment in launches, R&D and AI driven process redesign. The current year shows core operating profit and core EPS guidance maintained despite VYVANSE erosion, which signals a focus on protecting net margins while funding future growth drivers.
• ENTYVIO Pen’s inclusion on formulary with all three large US pharmacy benefit managers at commercial coverage of more than 80%, together with Takeda’s expectation of maintaining leadership share in a competitive IBD market, supports the existing GI franchise, which remains an important contributor to revenue and cash flow during the transition to the new product cycle.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Takeda Pharmaceutical compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Takeda Pharmaceutical's revenue will grow by 4.3% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 2.5% today to 8.3% in 3 years time.
• The bullish analysts expect earnings to reach ¥423.0 billion (and earnings per share of ¥267.79) by about April 2029, up from ¥112.9 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as ¥168.8 billion.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 32.8x on those 2029 earnings, down from 82.4x today. This future PE is greater than the current PE for the JP Pharmaceuticals industry at 16.0x.
• The bullish analysts expect the number of shares outstanding to grow by 0.38% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.81%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Loss of exclusivity for high margin products such as VYVANSE and the anticipated ENTYVIO biosimilar entry from the early 2030s could structurally pressure pricing and threaten Takeda's plan to have new launches more than offset these effects, which could weigh on long term revenue and earnings.
• Multiple late stage programs, including oveporexton, rusfertide, zasocitinib and eight broader pipeline assets, all need regulatory approvals and successful commercial uptake in competitive markets. Any setbacks, slower adoption or weaker positioning versus alternatives could reduce the expected contribution to revenue growth and limit improvement in net margins.
• Takeda plans to increase R&D and launch related spending, including higher costs tied to the Innovent Biologics oncology assets and other programs. If cost efficiencies do not continue to offset this, higher ongoing operating expenses could compress core operating profit and restrict earnings.
• Exposure to pricing and policy pressures in key markets, including MFN discussions and IRA related price negotiations on ENTYVIO in the US and government driven utilization guidelines for albumin in China, could limit pricing power across gastroenterology and plasma derived therapies, affecting revenue and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Takeda Pharmaceutical is ¥7544.0, which represents up to two standard deviations above the consensus price target of ¥5850.2. This valuation is based on what can be assumed as the expectations of Takeda Pharmaceutical's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥7800.0, and the most bearish reporting a price target of just ¥4700.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be ¥5072.4 billion, earnings will come to ¥423.0 billion, and it would be trading on a PE ratio of 32.8x, assuming you use a discount rate of 4.8%.
• Given the current share price of ¥5888.0, the analyst price target of ¥7544.0 is 22.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.